Literature DB >> 6617682

The effect of pindolol on the two years mortality after complicated myocardial infarction.

.   

Abstract

The effect of oral pindolol 15 mg daily was compared with placebo in 529 patients who had electrical and/or mechanical complications after an acute myocardial infarction. The study was multicentric (five in Sweden, two in Australia) and patients were allocated in a stratified manner to placebo (266 patients) or pindolol (263 patients). Treatment was started 1--21 days after infarction and patients were followed for 2 years. Forty-seven patients (17.7%) in the placebo group and 45 patients (17.1%) in the pindolol group died. In patients who commenced therapy later than 5 days after myocardial infarction mortality was 18% lower in the pindolol group and there was an even greater difference in patients who commenced therapy after 12 days. Patients who were on digitalis therapy had a lower mortality if treated with pindolol. The apparent improvement in prognosis in patients treated in Sweden compared to Australia may have been due to later entry of patients. This study suggests that improvement in prognosis when beta blocking drugs are given after myocardial infarction may only apply to certain groups of patients. No benefit is gained by commencing an oral beta blocking drug immediately and such therapy need not be started before 1 week or more after the myocardial infarct.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617682

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  18 in total

Review 1.  Drugs used in secondary prevention after myocardial infarction: case presentation.

Authors:  S Maxwell; W S Waring
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 2.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 3.  An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention.

Authors:  V Hinstridge; T M Speight
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 4.  Choosing the right beta-blocker. A guide to selection.

Authors:  J R Hampton
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 5.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

6.  [How many beta-receptor blockers does the physician need?].

Authors:  D Palm
Journal:  Klin Wochenschr       Date:  1987-03-16

Review 7.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

8.  Effect of adrenaline on myocardial oxygen consumption during selective and non-selective beta-adrenoceptor blockade comparison of atenolol and pindolol.

Authors:  H Ihlen; S Simonsen; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis.

Authors:  Angela M Thompson; Tian Hu; Carrie L Eshelbrenner; Kristi Reynolds; Jiang He; Lydia A Bazzano
Journal:  JAMA       Date:  2011-03-02       Impact factor: 56.272

Review 10.  When is drug therapy warranted to prevent sudden cardiac death?

Authors:  B N Singh
Journal:  Drugs       Date:  1991       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.